Universidade Federal do Rio Grande do Norte
ufrn.brTotal trials
84
Active
7
Phase 3
1
Total enrollment
3,754
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| N,N-Dimethyltryptamine | — | — | — | — | 3 |
Next readouts
- 2027-02-01
Top conditions
- Low Back Pain9
- Stroke5
- Asthma5
- Transcranial Direct Current Stimulation4
- Mucositis3
- Neuromuscular Performance and Balance3
- Patellofemoral Pain Syndrome3
- Gait Disorders, Neurologic2
Frequently asked questions about Universidade Federal do Rio Grande do Norte
- How many clinical trials does Universidade Federal do Rio Grande do Norte have on ClinicalTrials.gov?
- Universidade Federal do Rio Grande do Norte is listed as the lead sponsor on 84 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universidade Federal do Rio Grande do Norte's trials are in Phase 3?
- 1 of Universidade Federal do Rio Grande do Norte's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Universidade Federal do Rio Grande do Norte focus on?
- Universidade Federal do Rio Grande do Norte's most-studied conditions on ClinicalTrials.gov are Low Back Pain, Stroke, Asthma, Transcranial Direct Current Stimulation, Mucositis.
- When are Universidade Federal do Rio Grande do Norte's next clinical trial readouts?
- Universidade Federal do Rio Grande do Norte has 1 upcoming primary-completion readout tracked here; the soonest is “Inhaled DMT for Major Depressive Disorder”, expected around 2027-02-01.